RETENTION RATES OF ADALIMUMAB, ETANERCEPT AND INFLIXIMAB AS FIRST AND SECOND-LINE BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY PRACTICE: THE MAINTAIN STUDY

被引：0
|
作者：
Frazier-Mironer, A. [1 ]
Cantagrel, A. [2 ]
Combe, B. [3 ]
Deschamps, V. [4 ]
Dougados, M. [5 ]
Flipo, R. -M. [6 ]
Logeart, I. [4 ]
Mariette, X. [7 ]
Schaeverbeke, T. [8 ]
Sibilia, J. [9 ]
Le Loet, X. [10 ]
机构：
[1] Univ Hosp, Paris, France
[2] Univ Hosp, Toulouse, France
[3] Univ Hosp, Montpellier, France
[4] Pfizer, Paris 14, France
[5] Univ Hosp, Cochin, Kerala, India
[6] Univ Hosp, Lille, France
[7] Univ Hosp, Le Kremlin Bicetre, France
[8] Univ Hosp, Bordeaux, France
[9] Univ Hosp, Strasbourg, France
[10] Univ Hosp, Rouen, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [1] Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice
    Frazier-Mironer, Aline
    Dougados, Maxime
    Mariette, Xavier
    Cantagrel, Alain
    Deschamps, Veronique
    Flipo, Rene Marc
    Logeart, Isabelle
    Schaeverbeke, Thierry
    Sibilia, Jean
    Le Loet, Xavier
    Combe, Bernard
    [J]. JOINT BONE SPINE, 2014, 81 (04) : 352 - 359
  • [2] Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
    Soubrier, Martin
    Pereira, Bruno
    Fan, Angelique
    Frayssac, Thomas
    Couderc, Marion
    Malochet-Guinamand, Sandrine
    Mathieu, Sylvain
    Tatar, Zuzana
    Tournadre, Anne
    Dubost, Jean-Jacques
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (11) : 1986 - 1992
  • [3] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS FIRST-OR SECOND-LINE BIOTHERAPIES FOR SPONDYLOARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)
    Soubrier, M.
    Castagne, B.
    Pereira, B.
    Fan, A.
    Frayssac, T.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Tatar, Z.
    Tournadre, A.
    Dubost, J-J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1297 - 1297
  • [4] Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience
    Soubrier, Martin
    Pereira, Bruno
    Frayssac, Thomas
    Fan, Angelique
    Couderc, Marion
    Malochet-Guinamand, Sandrine
    Mathieu, Sylvain
    Tatar, Zuzana
    Tournadre, Anne
    Dubost, Jean-Jacques
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (11) : 1924 - 1932
  • [5] Real-World Switching Patterns in Rheumatoid Arthritis Patients Receiving Abatacept, Adalimumab, Etanercept or Infliximab As Second-Line Biologic Therapy
    Meissner, Brian
    Rosenblatt, Lisa
    Trivedi, Digisha
    You, Min
    Hebden, Tony
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S857 - S857
  • [6] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)
    Soubrier, M.
    Fan, A.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Giraud, C.
    Tournadre, A.
    Dubost, J. -J.
    Pereira, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1756 - 1756
  • [7] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS 1ST-OR 2ND-LINE BIOTHERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE
    Soubrier, M.
    Pereira, B.
    Frayssac, T.
    Fan, A.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Tatar, Z.
    Tournadre, A.
    Dubost, J. -J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 813 - 813
  • [8] The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Kupper, H. H.
    Van de Laar, M. A. F. J.
    De Rooij, D. J. R. A.
    De Gendt, C. M.
    Jansen, T. L.
    Ronday, K. H.
    Bruse, H. L. C.
    Moolenburgh, J. D.
    Janson, M.
    Van Oijen, P. C. M.
    Adang, E. M.
    Van Riel, P. L. C. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [9] Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice
    Ramirez-Herraiz, E.
    Escudero-Vilaplana, V.
    Alanon-Plaza, E.
    Trovato-Lopez, N.
    Herranz-Alonso, A.
    Morell-Baladron, A.
    Sanjurjo-Saez, M.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : 559 - 565
  • [10] Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First-or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept.
    Johnston, S.
    Lobo, F.
    McMorrow, D.
    Fowler, R.
    Smith, D.
    Nadkarni, A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S40 - S40
12345